- In March 2024, AstraZeneca announced the acquisition of Fusion Pharmaceuticals for up to USD 2.4 billion, aiming to advance in the field of radiopharmaceuticals by delivering radioactive isotopes directly to cancer cells
- In May 2024, Intermountain Health and PharmaLogic Holdings Corp. partnered to develop novel radiopharmaceuticals for cancer diagnosis, enhancing diagnostic capabilities in oncology
- In July 2024, Curium submitted a New Drug Application (NDA) for its lutetium-177 (Lu-177) DOTATATE radiopharmaceutical, aiming to treat somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
- In July 2024, Nusano Inc. and PharmaLogic Holdings Corp. entered into a supply agreement to enhance the availability of medical radioisotopes, ensuring a more efficient and reliable supply for pharmaceutical products
- In October 2024, Siemens Healthineers secured a deal to purchase part of Novartis's Advanced Accelerator Applications (AAA) business for over €200 million, bolstering its PET radiopharmaceutical business by supplying critical radioactive chemicals for cancer scans
